Christophe Le Tourneau

43PUBLICATIONS
235CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursNeurosciences not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Oct 19, 2026
H3K4me1-Mediated Epigenomic Priming of Chemoresistant Tumor States in Ovarian Cancer.

|Sep 15, 2026
A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial.

|Sep 15, 2026
SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer.

|Dec 22, 2025
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Danny Rischin, Aaron R Hansen, Ezra E W Cohen

|Nov 12, 2025
An Extracellular Matrix-Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation.

Isabella Hofer, Yann Kieffer, Arianna Mencattini

|Sep 12, 2025
Acceptance of external control arms by HTA agencies: a review of oncology submissions in France, England, Germany and Norway from 2021 to 2023.

Matthias Monnereau, Jean-Pierre Delord, Stefan Michiels

Pageof 8

Frequent Collaborators

10 joint publications

Maud Kamal

8 joint publications

Nicolas Servant

6 joint publications

Fabrice Andre

4 joint publications

Claire Bonneau